AUT 00063

Drug Profile

AUT 00063

Alternative Names: AUT-00063

Latest Information Update: 09 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Autifony Therapeutics
  • Class Small molecules
  • Mechanism of Action Shaw potassium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Hearing loss; Tinnitus

Highest Development Phases

  • Phase II Hearing loss; Tinnitus

Most Recent Events

  • 01 Apr 2017 Autifony Therapeutics completes a phase II trial in Hearing loss in United Kingdom (PO) (NCT02832128)
  • 01 Jun 2016 Autifony Therapeutics completes a phase II trial for Hearing loss (In adults, In the elderly) in USA (NCT02345031)
  • 10 Mar 2016 Phase-II clinical trials in Hearing loss in United Kingdom (PO) (EudraCT2015-003929-34)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top